Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Biogaia Adr Class B BIOGY

Healthcare Biotechnology
Biogaia AB is a Sweden-based healthcare company that is engaged in the development and sell of probiotic products. The Company develops, markets and sells probiotic products with documented health benefits. The products are primarily based on different strains of the lactic acid bacterium Limosilactobacillus reuteri. The Company’s activities are divided into three segments: The Paediatrics... see more

Recent & Breaking News (PINL:BIOGY)

Research and Markets: Asia-Pacific Digital Wound Measurement Devices Market Outlook to 2020: Key players covered include ARANZ Medical Limited

Business Wire December 10, 2014

FDA Grants Cytori Conditional Approval for a U.S. Pivotal Clinical Trial in Scleroderma

Business Wire December 10, 2014

Cure Duchenne Offers Continued Support to BioMarin for Duchenne Research

Business Wire December 10, 2014

Research and Markets: EU5 Esophagoscopes & Gastroscopes Market Outlook to 2020: Key players covered include Olympus, Hoya, Fujifilm and KARL STORZ GmbH & Co

Business Wire December 10, 2014

Cellceutix: Prurisol(TM) for Psoriasis -- FDA Agrees That Phase 2 Study May Begin

Marketwired December 10, 2014

Research and Markets: Asia-Pacific Wound Debridement Devices Market Outlook to 2020: Key players covered include Smith & Nephew, Zimmer Holdings and Soring

Business Wire December 10, 2014

Cancer Genetics, Inc. Strengthens Clinical Trials Leadership Team With Hire of Rob Fannon as Vice President of Operations

GlobeNewswire December 10, 2014

Luspatercept Data on Myelodysplastic Syndromes Selected for "Best of ASH" by the American Society of Hematology

Business Wire December 10, 2014

Report: Demand Surges for Biologics Production As Capacity Nears Limit

PR Newswire December 10, 2014

Immunovaccine Receives FDA Fast Track Designation for DPX-Survivac for Treatment of Ovarian Cancer

Marketwired December 10, 2014

Soligenix Appoints Oreola Donini, PhD, as Chief Scientific Officer

PR Newswire December 10, 2014

Cystic Fibrosis Foundation Therapeutics Announces $15 Million Research Collaboration with Shire for Development of Novel CF Treatment

PR Newswire December 10, 2014

NIH Publishes Results of Preclinical Collaboration with ChromaDex Showing Potential Benefit of Nicotinamide Riboside

PR Newswire December 10, 2014

Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announce Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors

Business Wire December 10, 2014

Research and Markets: Hereditary Angioedema (HAE) - Pipeline Review, H2 2014

Business Wire December 10, 2014

Rapid Micro Biosystems Announces Availability of Bi-Directional LIMS Integration

GlobeNewswire December 10, 2014

Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC(R) in Prostate Cancer

GlobeNewswire December 10, 2014

Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC® in Prostate Cancer

Thomson Reuters ONE December 10, 2014

INGDAN.com of Cogobuy Holds First IDEAS Cross Border Summit on Internet and Internet of Things Industry

PR Newswire December 9, 2014

Center for Medicine in the Public Interest & Scientific American Worldview Honor Top Medical Innovators in Hematology

Business Wire December 9, 2014